Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

A practical review of the neuropathology and neuroimaging of multiple sclerosis.
Unusual case of gastroparesis leading to severe gastromegaly with demyelinating disease as a rare cause.
A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis.
Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials.
An observational study to assess persistence, adherence, quality of life, and treatment satisfaction in patients beginning therapy with the Avonex® PEN™ (PERSIST)
Changes to anti-JCV antibody levels in a Swedish national MS cohort.
Rituximab: Don't Count It Out as MS Treatment
Diffuse and heterogeneous T2-hyperintense lesions in the splenium are characteristic of neuromyelitis optica.
Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects with Multiple Sclerosis
Amiloride Clinical Trial In Optic Neuritis (ACTION) protocol: a randomised, double blind, placebo controlled trial.
Cancer risk in multiple sclerosis: findings from British Columbia, Canada.
FDA warns about seizures linked to MS drug
VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells.
The effects of massage therapy on multiple sclerosis patients' quality of life and leg function.
Periventricular lesions help differentiate neuromyelitis optica spectrum disorders from multiple sclerosis.
Phenytoin (Dilantin) and acupuncture therapy in the treatment of intractable oral and facial pain.
Multiple sclerosis and oligodendroglioma: an exceptional association.
CLARITY – Safety and Efficacy of Oral Cladribine in Subjects with Relapsing-remitting Multiple Sclerosis (MS)
The little compound that could: how phenytoin changed drug discovery and development.
Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
Reproductive issues in women with multiple sclerosis: ethical considerations.
Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.
Self-perceived performance and satisfaction with performance of daily activities in persons with multiple sclerosis following interdisciplinary rehabilitation.
The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat.
Confounding in association studies: month of birth and multiple sclerosis.

Pages